Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution

Davis, Kristen; Wood, Sarah; Dill, Emily; Fesko, Yuri; Bitting, Rhonda L.; Harrison, Michael R.; Armstrong, Andrew J.; Moul, Judd W.; George, Daniel J.

doi:10.1188/15.cjon.297-303

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endocytosis is an approach for cell engineering in which autologous cells are treated with proteins, drugs or nanoparticles in vitro , followed by reinfusion to the body. Depending on the phagocytosed substances, the representative approaches include vaccine endocytosis for antigen presentation and nanoparticle endocytosis for drug delivery 110-112.…”

Section: Engineering Cells Via Endocytosis-mediated Functionalizationmentioning

confidence: 99%

Advances in Engineering Cells for Cancer Immunotherapy

Shen

et al. 2019

Theranostics

View full text Add to dashboard Cite

Cancer immunotherapy aims to utilize the host immune system to kill cancer cells. Recent representative immunotherapies include T-cell transfer therapies, such as chimeric antigen receptor T cell therapy, antibody-based immunomodulator therapies, such as immune checkpoint blockade therapy, and cytokine therapies. Recently developed therapies leveraging engineered cells for immunotherapy against cancers have been reported to enhance antitumor efficacy while reducing side effects. Such therapies range from biologically, chemically and physically -engineered cells to bioinspired and biomimetic nanomedicines. In this review, advances of engineering cells for cancer immunotherapy are summarized, and prospects of this field are discussed.

show abstract

Section: Engineering Cells Via Endocytosis-mediated Functionalizationmentioning

confidence: 99%

Advances in Engineering Cells for Cancer Immunotherapy

Shen

et al. 2019

Theranostics

View full text Add to dashboard Cite

show abstract

“…The PAP protein shows high homology between murine species and humans, suggesting that the anti-tumor immune responses elicited in murine models might potentially be utilized in producing prostate cancer vaccines for humans (Saif et al, 2014). In addition, the capacity of the PAP as a target antigen has been demonstrated through an FDA-approved autologous cell-based vaccine (Provenge®, Sipuleucel-T) to increase the overall survival of patients with advanced prostate cancer with enhancement of anti-tumor effect (Gupta et al, 2011;Kristen et al, 2015; Madan et al, 2013;Tian et al, 2018). Also, PSA is an attractive target antigen for immunotherapy due to its highly speci c expression in prostatic tissues for inducing cytotoxic T-cell responses against prostate cancer cells (Balk et al, 2003;Correale et al, 1997;Gulley et al, 2002;Karan, 2013;Roos et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice

Kim

Kang

et al. 2023

Plant Cell Rep

View full text Add to dashboard Cite

Prostate speci c antigen (PSA) and prostatic acid phosphatase (PAP) have been considered as immunotherapeutic antigens for prostate cancer. The use of a single antigenic agent is unlikely to be effective in eliciting immunotherapeutic responses due to the heterogeneous and multifocal nature of prostate cancer. Thus, multiple antigens have been combined to enhance their anti-cancer effects. In the current study, PSA and PAP were fused to the crystallizable region (Fc region) of immunoglobulin G1 and tagged with KDEL, the endoplasmic reticulum (ER) retention signal motif, to generate PSA-FcK and PAP-FcK, respectively, and were transiently co-expressed in Nicotiana benthamiana. Western blot analysis con rmed the co-expression of PSA-FcK and PAP-FcK (PSA-FcK+PAP-FcK) with a 1:3 ratio in the coin ltrated plants. PSA-FcK, PAP-FcK, and PSA-FcK+PAP-FcK proteins were successfully puri ed from N. benthamiana by protein A a nity chromatography. ELISA showed that anti-PAP and anti-PSA antibodies successfully detected PAP-FcK and PSA-FcK, respectively, and both detected PSA-FcK+PAP-FcK. Surface plasmon resonance (SPR) analysis con rmed the binding a nity of the plant-derived Fc fusion proteins to FcγRI/CD64. Furthermore, we also con rmed that mice injected with PSA-FcK+PAP-FcK produced both PSA and PAP-speci c IgGs, demonstrating their immunogenicity. This study suggested that the transient plant expression system can be applied to produce the dual-antigen Fc fusion protein (PSA-FcK+PAP-FcK) for prostate cancer immunotherapy. Key MessagePAP-FcK and PSA-FcK prostate cancer antigenic proteins transiently co-expressed in plant induce their speci c humoral immune responses in mice.

show abstract

Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities

et al. 2017

View full text Add to dashboard Cite

Prostate cancer is the most common cancer in men by way of diagnosis and a leading cause of cancer-related deaths. Early detection and intervention remains key to its optimum clinical management. This review provides the most updated information on the recent methods of prostate cancer screening, imaging and treatment modalities. Wherever possible, clinical trial data has been supplemented to provide a comprehensive overview of current prostate cancer research and development. Considering the recent success of immunotherapy in prostate cancer, we discuss cell, DNA and viruses based, as well as combinatorial immunotherapeutic strategies in detail. Furthermore, the potential of nanotechnology is increasingly being realized, especially in prostate cancer research, and we provide an overview of nanotechnology-based strategies, with special emphasis on nanotheranostics and multifunctional nanoconstructs. Understanding these recent developments is critical to the design of future therapeutic strategies to counter prostate cancer.

show abstract

Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution

Cited by 5 publications

References 10 publications

Advances in Engineering Cells for Cancer Immunotherapy

Advances in Engineering Cells for Cancer Immunotherapy

Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice

Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities

Contact Info

Product

Resources

About